Vitronectin Antibody (Monoclonal)

A murine monoclonal antibody to human Vitronectin.


Product Specifications

Citations 3
Clonality

Monoclonal

Immunogen Purified human protein.
Applications See citations and technical data sheet for application info.
Concentration 1.0-1.2 mg/mL
Conjugate Unconjugated
Cross Reactivity

Human

Ordering Information

For Research Use Only in the United States. Not for use in diagnostic procedures.
Catalog Number A237
Catalog Number (CE) N/A
Size 100 µl
Price (USD) $365.00
Price (EURO) 330,00 €

Contact us

US Phone+1 (858) 552 1100
EU Phone+353 (91) 412 474
US Emailcontact-us@quidelortho.com
EU Emailcontact-emea@quidelortho.com

Specifications

Description

A murine monoclonal antibody to human Vitronectin.

Size 100 µl
Concentration

1.0-1.2 mg/mL

Applications See citations and technical data sheet for application info.
Form Liquid. Borate Buffered Saline (pH 8.4 ± 0.2), with ≤ 0.1% Sodium Azide.
Clonality Monoclonal
Immunogen Purified human protein.
Conjugate Unconjugated
Cross Reactivity Human
Isotype IgG1k
Purity ≥ 95% by SDS PAGE
Source

Mouse

Specificity This monoclonal antibody was raised against purified human S Protein (Vitronectin).
Storage

Short term (30 days) 4˚C. Long term at or below –20˚C.

Background

In contract to membrane-formed C5b-9 complexes, C5b-9 complexes formed in the fluid phase contain an additional protein, the S protein. Subsequently, it was found that isolated S protein inhibited C5b-9 attachment. S protein functions like a “membrane analogue” in that it binds to the binding site generated on assembly of C5b-9 and is required for insertion of the complex into the membrane. As a result, SC5b-7, SC5b-8 or SC5b-9 complexes are formed which have lost their membrane-binding capacity. When the S protein was cloned and sequenced, it was found to be identical to Vitronectin. Within the complement cascade, Vitronectin not only inhibits attachment of C5b-9 to target cells, but also prevents C9 polymerization. The biological function of Vitronectin is to minimize complement-mediated attack of cells in the vicinity of an ongoing complement attack. This may be relevant, not only during the generation of bactericidal activity in the case of infection, but also in autoimmune disease, immune complex disease, or inflammatory lesions, where complement is readily activated by dead or dying cells, exposed basement membranes or matrix proteins. S protein is present in human plasma at an approximate concentration of 150 µg/mL.